David Roman
Stock Analyst at Goldman Sachs
(1.97)
# 2,887
Out of 4,832 analysts
39
Total ratings
40.91%
Success rate
-5.91%
Average return
Main Sectors:
Stocks Rated by David Roman
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| ZBH Zimmer Biomet Holdings | Maintains: Neutral | $120 → $104 | $97.49 | +6.68% | 2 | May 6, 2025 | |
| TDOC Teladoc Health | Maintains: Buy | $13 → $10 | $7.62 | +31.23% | 4 | May 1, 2025 | |
| GEHC GE HealthCare Technologies | Maintains: Buy | $94 → $82 | $73.83 | +11.07% | 3 | May 1, 2025 | |
| KMTS Kestra Medical Technologies | Maintains: Neutral | $24 → $23 | $22.97 | +0.13% | 2 | Apr 16, 2025 | |
| HQY HealthEquity | Maintains: Neutral | $107 → $94 | $96.99 | -3.08% | 2 | Mar 27, 2025 | |
| ABT Abbott Laboratories | Maintains: Buy | $138 → $154 | $129.05 | +19.33% | 2 | Mar 4, 2025 | |
| TNDM Tandem Diabetes Care | Maintains: Neutral | $42 → $24 | $23.13 | +3.76% | 2 | Mar 3, 2025 | |
| SOLV Solventum | Maintains: Sell | $63 → $71 | $73.52 | -3.43% | 4 | Mar 3, 2025 | |
| LIVN LivaNova | Maintains: Buy | $64 → $55 | $44.06 | +24.83% | 2 | Mar 3, 2025 | |
| BAX Baxter International | Reinstates: Buy | $42 | $31.15 | +34.83% | 3 | Feb 26, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $91 → $124 | $139.78 | -11.29% | 2 | Feb 24, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $58 → $80 | $60.43 | +32.38% | 2 | Feb 10, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $384 → $427 | $387.53 | +10.19% | 2 | Jan 30, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $81 → $90 | $75.50 | +19.21% | 3 | Dec 5, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $90 | $102.95 | -12.58% | 1 | May 30, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $500 | $563.95 | -11.34% | 1 | May 30, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $274 | $175.34 | +56.27% | 1 | May 30, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Sell | $83 | $85.11 | -2.48% | 1 | May 30, 2024 |
Zimmer Biomet Holdings
May 6, 2025
Maintains: Neutral
Price Target: $120 → $104
Current: $97.49
Upside: +6.68%
Teladoc Health
May 1, 2025
Maintains: Buy
Price Target: $13 → $10
Current: $7.62
Upside: +31.23%
GE HealthCare Technologies
May 1, 2025
Maintains: Buy
Price Target: $94 → $82
Current: $73.83
Upside: +11.07%
Kestra Medical Technologies
Apr 16, 2025
Maintains: Neutral
Price Target: $24 → $23
Current: $22.97
Upside: +0.13%
HealthEquity
Mar 27, 2025
Maintains: Neutral
Price Target: $107 → $94
Current: $96.99
Upside: -3.08%
Abbott Laboratories
Mar 4, 2025
Maintains: Buy
Price Target: $138 → $154
Current: $129.05
Upside: +19.33%
Tandem Diabetes Care
Mar 3, 2025
Maintains: Neutral
Price Target: $42 → $24
Current: $23.13
Upside: +3.76%
Solventum
Mar 3, 2025
Maintains: Sell
Price Target: $63 → $71
Current: $73.52
Upside: -3.43%
LivaNova
Mar 3, 2025
Maintains: Buy
Price Target: $64 → $55
Current: $44.06
Upside: +24.83%
Baxter International
Feb 26, 2025
Reinstates: Buy
Price Target: $42
Current: $31.15
Upside: +34.83%
Feb 24, 2025
Maintains: Neutral
Price Target: $91 → $124
Current: $139.78
Upside: -11.29%
Feb 10, 2025
Maintains: Neutral
Price Target: $58 → $80
Current: $60.43
Upside: +32.38%
Jan 30, 2025
Maintains: Neutral
Price Target: $384 → $427
Current: $387.53
Upside: +10.19%
Dec 5, 2024
Maintains: Buy
Price Target: $81 → $90
Current: $75.50
Upside: +19.21%
May 30, 2024
Initiates: Buy
Price Target: $90
Current: $102.95
Upside: -12.58%
May 30, 2024
Initiates: Buy
Price Target: $500
Current: $563.95
Upside: -11.34%
May 30, 2024
Initiates: Buy
Price Target: $274
Current: $175.34
Upside: +56.27%
May 30, 2024
Initiates: Sell
Price Target: $83
Current: $85.11
Upside: -2.48%